Enliven Therapeutics, Inc. Common Stock

Day range

$40.96 – $42.18

Open

$41.58

Prev close

$41.52

Volume

367.09K

Market cap

$3.04B

Shares out

73.27M

P/E

—

P/S

—

P/B

3.40

P/FCF

—

ROE

-11.8%

ROA

-11.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Equity compensation grantOct 14, 2026

  Additionally, as a new outside director, Ms. Ball was granted stock options to purchase shares of the Company's common stock with a grant date fair value as determined in accordance with U.S. generally accepted accounting principles equal to approximately $650,000. These stock options will vest as to 1/36th of the total number of shares on each monthly anniversary of the grant date, subject to Ms. Ball's continued service through the applicable vesting date.

• Underwriting agreementJun 12, 2026

  On June 11, 2026, Enliven Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the "Representatives") of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale in a public offering (the "Offering") of 8,933,334 shares of the Company's common stock.

• Clinical trial resultsJun 11, 2026

  Encouraging ELVN-001 Efficacy Data by 24 Weeks - Of the 90 patients enrolled in the Phase 1b, 78 had typical BCR::ABL1 transcripts and had at least one post-baseline transcript; 69 patients were evaluable for major molecular response (MMR) by 24 weeks. Overall MMR 54% (n=69) in Phase 1b and 61% (n=28) in Phase 1b 80 mg QD Cohort.

• Annual meeting resultsJun 10, 2026

  Enliven Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. Proposal 1: Election of Two Class III Directors... Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm... Proposal 3: Amendment to the Amended and Restated Certificate of Incorporation... Proposal 4: Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers... Proposal 5: Approval, in an Advisory (Non-Binding) Vote, of the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company's Named Executive Officers

• Director departureJan 7, 2026

  On January 6, 2026, Andrew Phillips, Ph.D. informed the Board that he was resigning from the Board, the Audit Committee of the Board and the Nominating Committee, effective on January 7, 2026. Dr. Phillips' resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Days to cover

5.5

Short interest

10.36M

Avg volume

1.89M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
  positiveGlobeNewswire Inc.· Sep 8, 2026
• What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
  neutralThe Motley Fool· Jun 27, 2026
• Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
  neutralThe Motley Fool· Jun 24, 2026
• Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
  neutralThe Motley Fool· Jun 1, 2026
• Enliven Posts Loss Beat and Cash Surge
  positiveThe Motley Fool· Aug 13, 2025